Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 in Paroxysmal Nocturnal Hemoglobinuria
NCT06238544Phase 2Active, not recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-5965 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoint: Adverse Events at 36 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
HRS-5965
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06238544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238544.